Literature DB >> 15375218

The human BCL6 transgene promotes the development of lymphomas in the mouse.

Beverly W Baron1, John Anastasi, Anthony Montag, Dezheng Huo, Rebecca M Baron, Theodore Karrison, Michael J Thirman, Sumit K Subudhi, Robert K Chin, Dean W Felsher, Yang-Xin Fu, Timothy W McKeithan, Joseph M Baron.   

Abstract

BCL6, a gene on chromosome 3, band q27, encodes a zinc finger transcriptional repressor that is needed for germinal center formation and has been implicated in the pathogenesis of some human lymphomas when it is mutated or involved in chromosomal rearrangements. To explore further the mechanisms of action of BCL6 in lymphomagenesis, we developed a transgenic mouse model mimicking a common translocation, the t(3, 14)(q27;q32), in human lymphomas. The transgenic mice develop normally and express the transgenic BCL6 protein constitutively in lymphocytes. A small fraction of the animals develop B and T cell lymphomas after a long latency period, but the incidence is dramatically enhanced following administration of N-ethyl-N-nitrosourea, a carcinogen that induces DNA mutations. The N-ethyl-N-nitrosourea-induced lymphomas spread widely, were exclusively T cell, expressed the BCL6 protein, and occurred only in the transgenic mice. Because BCL6 expression has been reported in a number of T cell tumors as well as in the more commonly occurring B cell lymphomas in humans, our transgenic mice provide a model for the study of human lymphomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375218      PMCID: PMC521136          DOI: 10.1073/pnas.0406138101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia.

Authors:  L H Castilla; L Garrett; N Adya; D Orlic; A Dutra; S Anderson; J Owens; M Eckhaus; D Bodine; P P Liu
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

2.  Genomic organisation and expression of BCL6 in murine B-cell lymphomas.

Authors:  C F Qi; M Hori; A E Coleman; T A Torrey; L Taddesse-Heath; B H Ye; S K Chattopadhyay; J W Hartley; H C Morse
Journal:  Leuk Res       Date:  2000-08       Impact factor: 3.156

3.  Non-Hodgkin lymphomas of mice.

Authors:  M Hori; S Xiang; C F Qi; S K Chattopadhyay; T N Fredrickson; J W Hartley; A L Kovalchuk; G W Bornkamm; S Janz; N G Copeland; N A Jenkins; J M Ward; H C Morse
Journal:  Blood Cells Mol Dis       Date:  2001 Jan-Feb       Impact factor: 3.039

Review 4.  B lymphoid neoplasms of mice: characteristics of naturally occurring and engineered diseases and relationships to human disorders.

Authors:  Herbert C Morse; Tom McCarty; Chen-Feng Qi; Ted A Torrey; Zohreh Naghashfar; Sisir K Chattopadhyay; Torgny N Fredrickson; Janet W Hartley
Journal:  Adv Immunol       Date:  2003       Impact factor: 3.543

5.  Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Anna Migliazza; Katia Basso; Jane Houldsworth; R S K Chaganti; Riccardo Dalla-Favera
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

6.  BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene.

Authors:  I S Lossos; R Warnke; R Levy
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

7.  Bethesda proposals for classification of lymphoid neoplasms in mice.

Authors:  Herbert C Morse; Miriam R Anver; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy L Harris; Elaine S Jaffe; Scott C Kogan; Ian C M MacLennan; Paul K Pattengale; Jerrold M Ward
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  B220+ double-negative T cells suppress polyclonal T cell activation by a Fas-independent mechanism that involves inhibition of IL-2 production.

Authors:  Abdel Rahim A Hamad; Abdiaziz S Mohamood; Crystal J Trujillo; Ching-Tai Huang; Emily Yuan; Jonathan P Schneck
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

9.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

10.  Selective expression of an acetylcholine receptor-lacZ transgene in synaptic nuclei of adult muscle fibers.

Authors:  J R Sanes; Y R Johnson; P T Kotzbauer; J Mudd; T Hanley; J C Martinou; J P Merlie
Journal:  Development       Date:  1991-12       Impact factor: 6.868

View more
  37 in total

1.  Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.

Authors:  Mingxing Teng; Scott B Ficarro; Hojong Yoon; Jianwei Che; Jing Zhou; Eric S Fischer; Jarrod A Marto; Tinghu Zhang; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2020-04-03       Impact factor: 4.345

2.  Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets.

Authors:  Micah D Gearhart; Connie M Corcoran; Joseph A Wamstad; Vivian J Bardwell
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Association of Ig/BCL6 translocations with germinal center B lymphocytes in human lymphoid tissues: implications for malignant transformation.

Authors:  Xuwei Yang; Koutetsu Lee; Jonathan Said; Xun Gong; Ke Zhang
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 5.  Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6.

Authors:  Saritha Kusam; Alexander Dent
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

6.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

Review 7.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

8.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

9.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.